ZURICH (Reuters) – Novartis aims to help manufacture more than 50 million doses of BioNTech’s COVID-19 vaccine in 2021 at its Stein, Switzerland fill-and-finish facility, the Swiss drugmaker said, after the European Union’s drug regulator approved the bottling plant.
(Reporting by John Miller; Editing by Chris Reese)
